Physician profile
Vanessa Narwani
NPI 1700243813
$3,783.57
in general payments reported to CMS, 2019-2025
29 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $117 · 2021: $113 · 2022: $366 · 2023: $160 · 2024: $673 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Long Term Medical Supply Or Device Loan: $19.98 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.37 |
| Long Term Medical Supply Or Device Loan | $19.98 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $542.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $537.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $420.87 | 2019-2025 | Evenity, Repatha, Repatha |
| Insulet Corporation | $398.21 | 2022-2025 | Omnipod, Omnipod |
| Corcept Therapeutics | $259.26 | 2024-2025 | Korlym |
| Abbott Laboratories | $191.23 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Sanofi-Aventis U.S. LLC | $176.40 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $165.03 | 2025 | Yorvipath |
| Ibsa Pharma INC. | $147.38 | 2024-2025 | Tirosint, Licart, Flector |
| Abbvie INC. | $125.48 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $117.08 | 2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $80.85 | 2021-2024 | Minimed 780g |
| Mannkind Corporation | $73.23 | 2019 | |
| Amneal Pharmaceuticals LLC | $73.06 | 2024-2025 | Unithroid |
| Tandem Diabetes Care, INC. | $67.73 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.79 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $46.67 | 2025 | Strensiq |
| Cequr Corporation | $40.00 | 2023-2024 | Cequr Simplicity |
| Astellas Pharma US INC | $38.81 | 2025 | Veozah |
| Neurocrine Biosciences, INC. | $38.16 | 2025 | |
| Beta Bionics, INC. | $37.58 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals LP | $36.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $28.78 | 2020-2021 | |
| Madrigal Pharmaceuticals | $18.71 | 2025 | Rezdiffra |
| Tolmar, INC. | $18.16 | 2025 | Jatenzo |
| Radius Health, INC. | $15.90 | 2025 | Tymlos |
| Amphastar Pharmaceuticals, INC. | $13.57 | 2025 | |
| Valeritas, INC. | $13.44 | 2019 | |
| Shire North American Group INC | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Narwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.